Midazolam, lorazepam, diazepam, and phenobarbital are available in both parenteral and oral formulations. These metabolites are subsequently glucuronidated and excreted in the urine. Concomitant use of fenofibric acid with CYP2C19 substrates, such as diazepam, has not been formally studied. Moderate Amoxapine may enhance the response to the effects of benzodiazepines and other CNS depressants. If seizures occur, amphetamine discontinuation may be necessary.
Can J Hosp Pharm. Dose equivalence of midazolam and triazolam. A psychometric study based on flicker sensitivity, reaction time and digit symbol substitution test. Eur J Clin Pharmacol. Lieberman JA, Tasman A. Handbook of Psychiatric Drugs. How they work and how to withdraw; The Ashton Manual. The Ashton Manual Online. Effect of age, gender, and obesity on midazolam kinetics. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.
Bioavailability of diazepam after intravenous, oral and rectal administration in adult epileptic patients. Br J Clin Pharmacol. Absolute bioavailability of oral and intramuscular diazepam: Phenobarbital pharmacokinetics and bioavailability in adults. A double-blind, randomized comparison of i. Use with caution parenteral and rectal formulations ; data not available oral formulations. Patients with liver disease: Use with caution parenteral and rectal formulations Mild to moderate hepatic insufficiency: Dose adjustment s may be required; however, no specific guidelines have been suggested.
Use should be limited to patients for whom alternative treatment options are inadequate, and the dose and duration should be as low and short as possible. Patients should be monitored for respiratory depression and sedation. Safety and efficacy have not been established in patients younger than 30 days parenteral formulations , 6 months oral formulations , and 2 years rectal formulations. If direct IV injection is not possible, treatment should be injected slowly through infusion tubing as close as possible to vein insertion.
The IV should be given slowly, over a 3 minute period at a rate of 0. After 15 to 30 minutes, the initial dosage may be repeated. The use of emulsion for injection formulations should be carefully considered in pediatric patient populations. This drug should be injected deeply into the muscle. Patients and caregivers should review administration steps included in the manufacturer product information. When used as a continuous infusion, the mixed product should be used within 6 hours.
When used as an injection, the dose should be drawn into a syringe immediately before administration. The concentrated solution should be dosed with the included calibrated dropper and mixed into liquids or semi-soft foods. When used for continuous infusion, the solution should be used immediately after mixing with infusion fluid. Adsorption into plastic infusion equipment may occur, but may be less than with other formulations.
When used as a continuous infusion, this formulation should be mixed with at least mL of sodium chloride or dextrose in glass bottles. Adsorption into plastic bags may occur. Patients should be regularly reassessed for continued need of treatment, especially when they are symptom-free. Anxiety Xanax , Cymbalta , Lexapro , alprazolam , atenolol , lorazepam , More